ArticleCurrent microbiology2025
β-Lactam Potentiating Activity, Molecular Docking, and ADMET Analysis of 3-Substituted Coumarins.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance is a pivotal issue in the treatment of bacterial infections. Thus, discovering alternative drugs is necessary to control antibiotic-resistant bacteria, such as β-lactamase-producing Staphylococcus aureus. Coumarins with C-3 modifications have different inhibitory effects on bacteria, including resistant ones. Here, we evaluate the in vitro and in silico potential of 3-substituted coumarins in inhibiting S. aureus β-lactamase. This study involved assays of antibacterial activity and association with ampicillin to control strains producing β-lactamase, studies of molecular docking with the blaZ-encoded β-lactamase, and analysis of absorption, distribution, metabolism, excretion, and toxicity (ADMET) of 3-substituted coumarins. The derivatives did not inhibit bacterial growth. However, they enhanced the ampicillin activity, reducing the inhibitory concentration by up to 93.75%. Molecular docking revealed the affinity of the compounds to the β-lactamase model and showed that coumarins interact with crucial amino acids for enzymatic activity, such as the Ser70 residue. The ADMET profiles showed favorable predictions and limitations of the derivatives, such as the distribution and higher number of toxicity alerts for coumarins C2 and C3. Therefore, our study highlights the ability of 3-substituted coumarins to inhibit S. aureus β-lactamase and the contribution of C-3 substituents to the resistance modulation and ADMET profile.
Indexed as
Identifiers
40736682What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.